The Market for Tissue and Organ Transplantation

Introduction
Study Goal And Objectives
Reasons For Doing The Study
Contributions Of The Study And For Whom
Scope And Format
Methodology
Information Sources
Author’s Credentials
Related Bcc Publications
Reports
Monthly Newsletters
Bcc On-Line Services
Summary
Organs
Tissues
Summary Table Us Organ And Tissue Transplantation Markets, Through 2007
Summary Figure Us Organ And Tissue Transplantation Markets, 2002 And 2007 ($ Millions)
General Trends
Overview
Importance Of The Industry
Organs
Table 1 Us Organ Transplants, Average 1 St Year Cost And Market Totals, Through 2007
Kidney
Liver
Heart
Lung
Intestine
Pancreas
Waiting Lists
Waiting Lists Grow Faster Than Numbers Of
Transplantations
International Trends
Limited Supply Puts Breaks On Transplantations
Table 2 Numbers Of Donated Cadavers By Region, 1997-2001
Tissues
Aging Baby Boomers Driving Market
Table 3 Tissue Grafting In The Us, Through 2007 (Number Of Procedures)
Figure 1 Issue Grafting In The Us, 2002 - 2007 (Number Of Procedures)
Cornea
Blood Stem Cells
Bone Allografts
Heart Valves
Vascular Tissue
Skin And Collagen
Larger Potential Markets, Same Limits On
Supply
Table 4 Potential And Expected Us Markets For Transplanted
Human Tissue, Through 2007 ($ Millions)
Table 4 (Continued)
Widespread Distrust Of For-Profit Companies
Could Retard Growth
More Regulation
Applications
The Transplantation Process
Preparation
Operation
Recuperation
Maintenance
Products In The Transplantation Process
Hla Tissue Typing
Organ Preservation Products
Anti-Rejection Drugs
Antibiotics
Post-Transplant Monitoring
Alternatives To Transplantation
Government Regulation And Patents
Evolution Of Transplantation
Tissue Typing
Immunosuppression
Preservation
Government Reimbursement Of
Transplantation Costs
Mechanical Organs
General Trends
Supply Management
Reducing Waste And Rejection
Increasing The Harvest
Table 5 Recovered Organs Not Used, 1995-1999
Table 6 Consented Organs Not Recovered, 1995-1999
Better Harvesting
Papworth Cocktail
Remembering The Ultimate Customer, The Patient On The Waiting List
Less Waste
Preservation
Rinse/Preservation Solutions
Table 7 Major Organ Preservation Solutions
Collins Solution
Viaspan
Celsior
Custodiol
Table 8 The North American And World Markets For Organ Preservation Solution (Except Papwork Cocktail), Through 2007
Market Size
Potential New Alternatives
Machine Perfusion
Waters Medical Systems
Bio-Preserve International
Transmedics, Inc
Non-Heart-Beating Donors
Testing
Blood Typing
Tissue Typing
Panel Reactive Antibodies (Pra)
Table 9 Types Of Typing
Advances
Table 10 Players In The Hla Typing Market
The Market For Histocompatibility Supplies And Services
Table 11 The Us Market For Tissue Typing Services, Through 2007 ($ Million)
Splitting The Market
Regulation
Plasmapheresis: Transplantation Without Matching
Antigens
Post-Transplant
Biotronik
Isis
Data Sciences
Reperfusion Injury
Fighting Rejection
Table 12 Number Of Patients In The Us Who Are On Waiting List
Because Of Graft Failure (Failure Of Previously Transplanted Organ), All Organs, 1995-1999
Table 13 Percent Of Us Patients On Waiting List By Organ Who Had A Previous Transplant, 1995-1999 (%)
Table 14 Us Organ Recipients Who Previously Had A Transplant, All Organs, 1995-1999
Immunosuppression
Market Size
Table 15 Worldwide Market For Immunosuppression, Through 2007
Table 16 Worldwide Sales Of Immunosuppressives By Company, 1999-2001 ($ Millions)
Crowded Market
Five Types Of Immunosuppressives
Table 17 Us Sales Of Immunosuppressives By Type, Through 2007* ($ Millions)
Figure 2 Us Sales Of Immunosuppressives By Type, 1999-2007 ($ Millions)
Table 18 World Sales Of Immunosuppressive By Type, Through 2007 ($ Million
Antiproliferatives
Calcineurin Inhibitors
Calcineurin Inhibitors (Continued)
Antibodies
Tor Inhibitors
Table 19 Experimental Immunosuppressives By Type
Clinical Testing
Generics
Governors, Corporate Executives Want To Let
Generics Compete Sooner
Governors, Corporate Executives Want To Let Generics
Compete Sooner (Continued)
Effect Of Shorter Monopoly Times On Transplantation Drug Research
State Prosecutors Target Drug Makers
International Patent Rights
Trips
Impact Of Waste Reduction On Supply
Transplantation Without Rejection
Tolerance
Antisense Therapy
Costimulation
Chimerism
University Of Pittsburgh
Massachusetts General Hospital And Biotransplant
Abgenix
Chimeric Therapies
Insurance
Fighting Infections
Table 20 Common Post-Transplant Infections
Table 21 Common Post-Transplant Drugs
Table 21 (Continued)
Table 22 Cost Of Transplant Antibiotics In The Us, Through 2007 ($ Millions)
Monitoring
Table 23 The World Market For Transplant Drug And Disease Monitoring Agents, Through 2007 ($ Millions)
The Efficiency Dividend
Table 24 Maximum Potential For Additional Organs Compared To Demand In The Us, 1999
Tissue
Finding More Supply
Expanding Traditional Sources: Getting More Cadavers
Spain Sets Donation Standard
Table 25 International Organ Donor Rates, 2000 (Per Million Of Population)
Even With Increased Donation, Waiting Lists Persist
Table 26 Transplantations And Waiting List Numbers In Spain, 2000
Reforms To Boost Donation
Presumed Consent
Table 27 Selected Countries And Type Of Consent
Donor Compensation
Tapping New Sources: Expanding Donation To New Nations And Living Donors
Shifting Cadaveric Donation
Table 28 Countries With Kidney Transplant Programs
Table 28 (Continued)
The Argentinean Collapse
Table 29 Kidney, Liver, Heart Transplants By Region, 2000
Table 29 (Continued)
More Competition Splinters Market
Organ Selling Meets Dammed Up Demand
Marketing Availability
Belgium And Austria
Costa Rica
South Africa
Pakistan
Cuba
Tissues
Effects Of Globalization
Living Donors
Table 30 Trends In Living And Cadaveric Donation In The Us Through 2007
Kidney Exchanges
Reimbursement For Costs
New Technologies
Organs From Animals: Xenotransplantation
Overcoming Hyperacute Rejection
Porcine Endogenous Retrovirus
Major Competitors
Political Problems
Artificial Organs
Reducing Demand
Cellular Transplants
The Challenge Of Aging Populations
Table 31 Growth Of Selected Population Groups In The Us, Through 2007 (Millions)
Organs
Kidneys
Table 32 Number Of Kidney Transplantations By Region, Through 2007
Table 33 The Us Kidney Transplant Market, Through 2007 ($ Millions)
Figure 3 The Us Kidney Transplant Market, 2002-2007 ($ Millions)
Table 34 The Top Four Kidney Transplant Programs In The Us, 2000 (By Number Of Procedures)
Table 35 Kidney Patient And Graft Survival, Us (%)
Table 36 Costs Per Year Due To End Stage Renal Disease, 1995-1999
Transplantation Too Rare To Be A Solution
Table 37 Waiting List Trends By Region, Through 2007
Shortage Is Worse In Japan
Cadaveric Donations Falling
Table 38 Number Of Kidney Transplantations In The Us From Living And Cadaveric Donors, Through 2007
Table 39 Kidney Transplantation In Norway From Living And Cadaveric Donors, Through 2007
Closing The Kidney Gap
Indications
Table 40 Leading Causes Of Kidney Failure (%)
Table 41 Leading Causes Of Kidney Transplantation (%)
International Trends
Older Recipients
Less Rejection
Table 42 Hazard Ratio For Graft Failure (1993 = 1)
Immunosuppression
Table 43 Estimated Us Market For Immunosuppressives For Kidney Transplant Patients, Through 2007
Advances
Chimerism
Alternatives
Mechanical
Medical
Animal
Cellular
Pancreas
Table 44 Growth Of Whole Pancreas Transplantation, Through 2007
Table 45 Us Whole Pancreas Transplantation Market, Through 2007 ($ Millions)
Figure 4 Us Whole Pancreas Transplantation Market, 2000-2007 ($ Millions)
Table 46 The Top Four Pancreas Transplant Programs In The Us, 2000 (Number Of Transplants)
Islet Cells
Table 47 International And Us Pancreas Graft Survival Rates (%)
A Breakthrough
Juvenile Diabetes Research Foundation
Drawbacks
Table 48 Pancreas Waiting List, Us, Through 2007
Immunosuppression
Controversy
Indications
Alternatives
Cell Encapsulation
Biohybrid Technologies
Circe Biomedical
Islet Technologies
Cultured Stem Cells
Medical
Nuerochem
Columbia University
Costs
Liver
Numbers
Table 49 Growth In Liver Transplants By Region, Through 2007
Table 50 Liver Transplant Market In The Us, Through 2007 ($ Millions)
Figure 5 Liver Transplant Market In The Us, 2000-2007 ($ Millions)
Table 51 The Top Four Liver Transplant Programs In The Us, 2000
Donors
Table 52 Trends In Living Donor Liver Transplants In The Us
Waiting List
Table 53 Growth In Liver Waiting Lists By Region, Through 2007
Table 54 Deaths On Liver Waiting List, Us, Through 2007
Indications
Causes Of Cirrhosis
Tissue Typing
Organ Recovery
Rejection
Table 55 Liver Transplant Survival Rates* (%)
Table 56 The Us Market For Immunosuppressants After Liver
Transplantation, First Year After Transplant Through 2007 ($ Millions)
Hepatitis B
History
Controversies
Liver Allocation
Alternatives
Medical
Artificial Livers
Chemical-Mechanical Livers
Hemotherapies
Hemocleanse
Bioartificial Livers
Cedars-Sinai Medical Center
Circe Biomedical
Algenix
Excorp Medical
Exten Corp
Organogenesis
Vitagen
Relative Costs
Table 57 Treatment Costs For Acute Liver Failure: Transplantation And Bioartificial Liver, Us, Through 2007 ($ Millions)
Figure 6 Treatment Costs For Acute Liver Failure: Transplantation And Bioartificial Liver, Us, 2000-2007 ($ Millions)
Regeneration Therapy
Heart
Table 58 Declining Numbers In Heart Transplantation By Region Through 2007
Table 59 Us Heart Transplant Market, Through 2007 ($ Millions)
Table 60 Top Four Us Heart Transplant Programs, 2000
Fewer Transplants Due To Tighter Supply
Cultural Backlash
Peak Year Was 1995
Waiting Lists Also Shrink
Table 61 Heart Waiting List Trends, Through 2007
Are Waiting List And Transplant Numbers Inflated?
Heart-Lung Numbers
Table 62 Trends In Heart-Lung Transplantation By Region, Through 2007
Table 63 Us Heart-Lung Transplant Market, Through 2007 ($ Millions)
Figure 7 Us Heart-Lung Transplant Market, 2000-2007 ($ Millions)
Table 64 The Top Three Us Combined Heart-Lung Transplant Programs, 2000
Table 65 Heart-Lung Waiting List Trends, Through 2007
Rejection
Table 66 International Heart And Lung Transplant Patient
Survival Rates (%)
Table 67 The Us Market For Anti-Rejection Drugs After Heart
Transplantation, First Year After Transplant ($ Millions)
Indications
Table 68 Leading Causes Of Heart Failure (%)
Tissue Typing
Preservation
Alternatives
Medical
Cholesterol Vaccine
Endothelian Antagonists
Animal
Surgical
Laser Revascularization
Mitral Valve Repair
Cardiac Support Devices
Mechanical
Thoratec
World Heart Corp
Micromed
Vad Market
Abiomed
Regeneration Trumps Replacement
Cellular
Bioheart
Lungs
Table 69 Trends In Lung Transplantations By Region, Through 2007
Table 70 Us Lung Transplantation Market, Through 2007 ($ Millions)
Figure 8 Us Lung Transplantation Market, 2000-2007 ($ Millions)
Table 71 The Top Four Us Lung Transplant Programs, 2000
Donation
Table 72 Recovered Organs Not Used, 1995-1999, Us
Waiting Lists
Table 73 Lung Waiting List Trends, Through 2007
Table 74 Reported Deaths On Lung Waiting List In Us, 1998-2001
Rejection
Table 75 International And Us Lung Transplant And Graft
Survival Rates* (%)
Table 76 The Us Market For Anti-Rejection Drugs After Lung Transplantation, First Year After Transplant ($ Millions)
Indications
Table 77 Leading Causes Of Chronic Lung Failure, 1995-1999 (%)
Preservation
Celsior
Hypothermosol
21 St Century Medicine
History
Alternatives
Medical
Retinoic Acid
Surgical
Cellular
Intestines
Table 78 Trends In Small Bowel Transplantation, Us, Through 2007
Table 79 Us Small Bowel Transplantation Market, Through 2007 ($ Millions)
Figure 9 Us Small Bowel Transplantation Market, 2000-2007 ($ Millions)
Table 80 The Top Four Us Small Bowel Transplant Programs, 2000
Poised For Growth
Table 81 Countries With Small Bowel Transplant Programs
Rejection
Table 82 International Intestine Transplant Survival Rates (%)
Types Of Transplants
Table 83 Leading Causes Of Intestine Failure (%)
Indications
Immunosuppression
Table 84 The Us Market For Anti-Rejection Drugs After Small
Bowel Transplantation, First Year After Transplantation ($ Millions)
Patient Follow-Up
History
Alternatives
Medical
Mechanical
Cellular
Tissues
Eyes
Cornea
Table 85 Corneal Transplants In Specified Countries, 1997-2000
Table 86 Corneal Transplants And Market In The Us, Through 2007
Figure 10 Corneal Transplants And Market In The Us, 2001-2007 ($ Millions)
Donors
Table 87 Number Of Cornea Donors In Us
Waiting List
Us
Other Countries
Indications
Tissue Testing
Preservation
Cryopreservation
Immunosuppression
History
Alternatives
Surgical
Synthetic
Retinal Degeneration
Cellular Transplants
Gene Therapy
Electronic Implants
Blood Stem Cells
Numbers
Table 88 Bone Marrow Transplants, Us, 1995-1999
Table 89 Projected Us Bone Marrow Transplant Procedures, Through 2007
Autologous Passes Allogenic
Table 90 Worldwide Blood And Bone Marrow Transplant Patients, 1995-1998
Table 91 Projected Worldwide Blood And Bone Marrow Transplant Patients, Through 2007
Less Bone Marrow
Older Patients
Donors
Table 92 Home Countries Of Bmdw Members
Potential For Hla Testing
Table 93 The Number Of Bone Marrow Donors Per 10,000
Inhab
Table 93 (Continued)
Waiting List
Rejection
Table 94 Us Market For Immunosuppressants After Blood Stem Cell Transplantation, Through 2007 ($ Millions)
Indications
Cell Separation Systems
Immunosuppression
Abgenix
Biotransplant
Chimeric Therapies
Enzo Biochem
Protein Design Labs
Repligen
University Of Pennsylvania
History
First Successful Transplant
Donor Registry Established
Cord Blood
Alternatives
Expanding Cord Blood
Replicell
Bones
Table 95 Dominant Bone Replacement Procedures, Us, 1995-1999
Table 96 Projected Major Bone Replacement Procedures, Through 2007
Procedures
Market Totals
Table 97 Us And Worldwide Implant Market Growth, Through 2007 ($ Billions)
Figure 11 Us And Worldwide Implant Market Growth, 2002-2007 ($ Billions)
Bone Allografts
Table 98 Us And World Values Of Bone Allograft Market, Through 2007 ($ Millions)
Figure 12 Us And World Values Of Bone Allograft Market, 2002-2007 ($ Millions)
Products
Demineralized Bone Matrix
Machined Implants
Table 99 Us Sales Of Bone Allografts By Type, Through 2007 ($ Millions)
Figure 13 Us Sales Of Bone Allografts By Type, 2000-2007 ($ Millions)
Donors
Mandatory Referrals
Public Cynicism
Donor Compensation
Indications
Tissue Testing
Preventing Infection
Preservation
History
Competition
Alternatives
Animal Bone Grafts
Medical
Synthetics
Orthovita
Exactech
Spine Wave
Regeneration
Bone-Growth Factors
Medtronic
Collagen Sponges
Chrysalin
Bone Marrow
Peripheral Blood Stem Cells
Meniscus Allografts
Collagen Alternative
Regulation
State Regulation
Rules For Obtaining Consent
Replacement Heart Valves, Arteries And Other
Vessels
Table 100 Number Of Heart Valve Transplants And Bypass Operations In The Us, 1995-1999
Heart Valve Allograft Market
Table 101 Us And World Heart Valve Transplant Market, Through 2007
Tissue Valves Gain Popularity
Major Competitors
Vascular Grafts
Table 102 Projected Number Of Heart Valve Transplants And Bypass Operations In The Us, Through 2007
Donors
Valves From Morgues
Public Cynicism
International Trade
Waiting List
Indications
Heart Valves
Vascular Grafts
Tissue Testing
Preservation/Processing
History
Synthetics
Xenografts
Defects And Regulation
Advances
Heart Valves
Vascular Grafts
Alternatives
Animal
Heart Valves
Stentless Valves
Calcification
Surgical
Heart Valves
Coronary Bypass Grafts
Medical
Heart Valve And Vascular Disease
Mechanical/Synthetic
Heart Valves
Improving Blood Flow
Better Maintenance
Tri-Leaflet Valve
Vascular Grafts
Minimally Invasive Surgery
Engineered Tissue
Heart Valves
Vascular Grafts
Gene Therapy
Skin, Muscle, And Matrix
Table 103 Us Market Of Human Skin-Based Products, Through 2007
Skin
Indications
Table 104 Skin Grafts In The Us, 1995-1999
Burns
Wounds
Venous Ulcers
Table 105 Estimated Incidence Of Venous Ulcers In The Over 64 Population, Us, Through 2007
Diabetic Ulcers
Table 106 Estimated Incidence Of Diabetic Foot Ulcers, Us Pressure Ulcers
Urinary Incontinence And Other Uses
Table 107 Tendon, Cartilage, And Muscle Grafts, Us, 1995-1999 Cosmetic Surgery
Table 108 Cosmetic Surgery Trends In The Us, 1997-2001
Table 109 Growth In Us Of Popular Cosmetic Surgeries Making Use Of Donated Human Tissue, 1999-2001
Table 110 Projected Growth In Popular Us Cosmetic Surgery Markets For Skin Products, Through 2007 (Number Of
Proc
Donors
Public Cynicism
Waiting List
Rejection
Tissue Testing
Preservation
History
Alternatives
Animals
Biobrane
Oasis
Medical
Repifermin
Telomerase
Ulcer Inspections
Botox
Synthetic
Alloderm
Integra
Transcyte
Dermagraft
Apligraf
Orcel
Promogran Matrix Wound Dressing
Other Uses
Next Generation Products
Cultured Autologous Skin
Shriners Burn Hospital
Other Research
Regulation
Cellular Transplantation
Four Types Of Cells Offer Potential
Numbers
Donors
Rejection
Indications
History
Cancer Cells
Restrictions
Cellular Patents
New Rule Requires Showing Of Specific And
Substantial Utility
Courts Join Narrowing Trend
Festo Limits Doctrine Of Equivalents
Ranbaxy Takes One From Glaxosmithkline
Closer Look At Obviousness
Crowded Race Field
Alternatives
Company Directory
Aastrom Biosciences, Inc
Abgenix
Abiomed
Acorn Cardiovascular, Inc
Advanced Cell Technology
Advanced Tissue Sciences
Alexion Pharmaceutical
Algenix
Allosource
Amgen
Aortech International
Apotex Corporation Usa
Argus Biomedical Pty
Ariad Pharmaceuticals
Arrow International
Ats Medical Inc
Avant Immunotherapeutics
Avax Technologies
Aventis Pharma Us
Barr Laboratories
Bausch & Lomb
Baxter International Inc
Bertek Pharmaceutical
Bio Array Solutions
Bioheart, Inc
Biohybrid Technologies
Biolife Technologies, Inc
Biotest Diagnostics Corp
Biotransplant
Biotronik, Inc
Cardiogenesis
Cardion Pharmaceuticals, Inc
Cardiowest Technologies
Chimeric Therapies
Chrysalis Biotechnology
Circe Biomedical, Inc
Cook Biotechnology
Corixa Corp
Cr Bard
Cryolife
Curis
Depuy Acromed, Inc
Diacrin
Digene
Dynal Biotech
Edwards Life Sciences
Enzo Biochem
Enzon
Eon Labs, Inc
Exactech, Inc
Excorp
Exten Industries
Fujisawa Healthcare, Inc
Genentech
Genovision
Genzyme
Genzyme Transgenics Corp
Geron Corp
Gti, Inc
Guidant
Hemocleanse
Hemotherapies
Incara Pharmaceuticals
Infigen
Immerge Biotherapeutics
Ilex Oncology
Immucor
Immunex
Innogenetics, Inc
Integra Life Sciences
Interpore Cross International
Isis Pharmaceuticals, Inc
Islet Technologies
Isotis
Kriton Medical
L-Vad Technology, Inc
Layton Bioscience
Lifecell Corp
Lifenet
Mast Diagnostic
Medimmune
Medtronic
Merck & Co, Inc
Micromed Technology Inc
Muskuloskeletal Transplant Foundation (Mtf)
National Genetics Institute
Nextran
Nippon Kayaku Co
Novamont
Nuerochem Inc
Novartis Pharmaceutical
Odyssey Pharmaceuticals, Inc
One Lambda
Orchid Biosciences
Organogenesis
Orquest, Inc
Ortec International, Inc
Ortho Biotech Products, Lp
Orthologic Corp
Orthovita
Paradigm Genetics
Pel-Freez Clinical Systems, Llc
Pharmacia Corporation
Ppl Therapeutics Plc
Prometheus Laboratories Inc
Protein Design Labs
Protein Polymer Technologies, Inc
Pyrosequencing Ab
Quest Diagnostics
Questcor Pharmaceuticals, Inc
Regen Biologics
Regeneration Technologies
Repligen
Robbins Scientific
Roche (F Hoffmann-La Roche Ltd)
Roxane Laboratories, Inc
St Jude Medical
Sangstat
Select Therapeutics
Sidmak
Snia Group
Spinal Concepts, Inc
Spine Wave, Inc
Stem Cells, Inc
Stem Cell Technologies
Styker Corporation
Sulzer Carbomedics
Sulzer Orthopedics
Sulzer Spine-Tech
Tanox
Thoratec
Tutogen Medical, Inc
Twenty-First Century Medicine
Vitagen
Waters Medical Systems
World Heart Corp
Wyeth (Formerly American Home Products)
List Of Tables
Summary Table:
Us Organ And Tissue Transplantation Markets, Through 2007
Table 1 Us Organ Transplants, Average 1 St Year Cost And Market Totals, Through 2007
Table 2 Numbers Of Donated Cadavers By Region, 1997-2001
Table 3 Tissue Grafting In The Us, Through 2007 (Number Of Procedures)
Table 4 Potential And Expected Us Markets For Transplanted Human Tissue, Through 2007 ($ Millions)
Table 5 Recovered Organs Not Used, 1995-1999
Table 6 Consented Organs Not Recovered, 1995-1999
Table 7 Major Organ Preservation Solutions
Table 8 The North American And World Markets For Organ Preservation Solution (Except Papwork Cocktail), Through 2007
Table 9 Types Of Typing
Table 10 Players In The Hla Typing Market
Table 11 The Us Market For Tissue Typing Services, Through 2007 ($ Millions)
Table 12 Number Of Patients In The Us Who Are On Waiting List Because Of Graft Failure (Failure Of Previously Transplanted Organ), All Organs, 1995-1999
Table 13 Percent Of Us Patients On Waiting List By Organ Who Had A Previous Transplant, 1995-1999 (%)
Table 14 Us Organ Recipients Who Previously Had A Transplant, All Organs, 1995-1999
Table 15 Worldwide Market For Immunosuppression, Through 2007
Table 16 Worldwide Sales Of Immunosuppressives By Company, 1999-2001 ($ Millions)
Table 17 Us Sales Of Immunosuppressives By Type, Through 2007* ($ Millions)
Table 18 World Sales Of Immunosuppressive By Type, Through 2007 ($ Millions)
Table 19 Experimental Immunosuppressives By Type
Table 20 Common Post-Transplant Infections
Table 21 Common Post-Transplant Drugs
Table 22 Cost Of Transplant Antibiotics In The Us, Through 2007 ($ Millions)
Table 23 The World Market For Transplant Drug And Disease Monitoring Agents, Through 2007 ($ Millions)
Table 24 Maximum Potential For Additional Organs Compared To Demand In The Us, 1999
Table 25 International Organ Donor Rates, 2000 (Per Million Of Population)
Table 26 Transplantations And Waiting List Numbers In Spain, 2000
Table 27 Selected Countries And Type Of Consent
Table 28 Countries With Kidney Transplant Programs
Table 29 Kidney, Liver, Heart Transplants By Region, 2000
Table 30 Trends In Living And Cadaveric Donation In The Us, Through 2007
Table 31 Growth Of Selected Population Groups In The Us, Through 2007 (Millions)
Table 32 Number Of Kidney Transplantations By Region, Through 2007
Table 33 The Us Kidney Transplant Market, Through 2007 ($ Millions)
Table 34 The Top Four Kidney Transplant Programs In The Us, 2000 (By Number Of Procedures)
Table 35 Kidney Patient And Graft Survival, Us (%)
Table 36 Costs Per Year Due To End Stage Renal Disease, 1995-1999
Table 37 Waiting List Trends By Region, Through 2007
Table 38 Number Of Kidney Transplantations In The Us From Living And Cadaveric Donors, Through 2007
Table 39 Kidney Transplantation In Norway From Living And Cadaveric Donors, Through 2007
Table 40 Leading Causes Of Kidney Failure (%)
Table 41 Leading Causes Of Kidney Transplantation (%)
Table 42 Hazard Ratio For Graft Failure (1993=1)
Table 43 Estimated Us Market For Immunosuppressives For Kidney Transplant Patients, Through 2007
Table 44 Growth Of Whole Pancreas Transplantation, Through 2007
Table 45 Us Whole Pancreas Transplantation Market, Through 2007 ($ Millions)
Table 46 The Top Four Pancreas Transplant Programs In The Us, 2000 (Number Of Transplants)
Table 47 International And Us Pancreas Graft Survival Rates (%)
Table 48 Pancreas Waiting List, Us, Through 2007
Table 49 Growth In Liver Transplants By Region, Through 2007
Table 50 Liver Transplant Market In The Us, Through 2007 ($ Millions)
Table 51 The Top Four Liver Transplant Programs In The Us, 2000
Table 52 Trends In Living Donor Liver Transplants In The Us
Table 53 Growth In Liver Waiting Lists By Region, Through 2007
Table 54 Deaths On Liver Waiting List, Us, Through 2007
Table 55 Liver Transplant Survival Rates* (%)
Table 56 The Us Market For Immunosuppressants After Liver Transplantation, First Year After Transplant Through 2007 ($ Millions)
Table 57 Treatment Costs For Acute Liver Failure: Transplantation And Bioartificial Liver, Us, Through 2007 ($ Millions)
Table 58 Declining Numbers In Heart Transplantation By Region, Through 2007
Table 59 Us Heart Transplant Market, Through 2007 ($ Millions)
Table 60 Top Four Us Heart Transplant Programs, 2000
Table 61 Heart Waiting List Trends, Through 2007
Table 62 Trends In Heart-Lung Transplantation By Region, Through 2007
Table 63 Us Heart-Lung Transplant Market, Through 2007 ($ Millions)
Table 64 The Top Three Us Combined Heart-Lung Transplant Programs, 2000
Table 65 Heart-Lung Waiting List Trends, Through 2007
Table 66 International Heart And Lung Transplant Patient Survival Rates (%)
Table 67 The Us Market For Anti-Rejection Drugs After Heart Transplantation, First Year After Transplant ($ Millions)
Table 68 Leading Causes Of Heart Failure (%)
Table 69 Trends In Lung Transplantations By Region, Through 2007
Table 70 Us Lung Transplantation Market, Through 2007 ($ Millions)
Table 71 The Top Four Us Lung Transplant Programs, 2000
Table 72 Recovered Organs Not Used, 1995-1999, Us
Table 73 Lung Waiting List Trends, Through 2007
Table 74 Reported Deaths On Lung Waiting List In Us, 1998-2001
Table 75 International And Us Lung Transplant And Graft Survival Rates* (%)
Table 76 The Us Market For Anti-Rejection Drugs After Lung Transplantation, First Year After Transplant ($ Millions)
Table 77 Leading Causes Of Chronic Lung Failure, 1995-1999 (%)
Table 78 Trends In Small Bowel Transplantation, Us, Through 2007
Table 79 Us Small Bowel Transplantation Market, Through 2007 ($ Millions)
Table 80 The Top Four Us Small Bowel Transplant Programs, 2000
Table 81 Countries With Small Bowel Transplant Programs
Table 82 International Intestine Transplant Survival Rates (%)
Table 83 Leading Causes Of Intestine Failure (%)
Table 84 The Us Market For Anti-Rejection Drugs After Small Bowel Transplantation, First Year After Transplantation ($ Millions)
Table 85 Corneal Transplants In Specified Countries, 1997-2000
Table 86 Corneal Transplants And Market In The Us, Through 2007
Table 87 Number Of Cornea Donors In Us
Table 88 Bone Marrow Transplants, Us, 1995-1999
Table 89 Projected Us Bone Marrow Transplant Procedures, Through 2007
Table 90 Worldwide Blood And Bone Marrow Transplant Patients, 1995-1998
Table 91 Projected Worldwide Blood And Bone Marrow Transplant Patients, Through 2007
Table 92 Home Countries Of Bmdw Members
Table 93 The Number Of Bone Marrow Donors Per 10,000 Inhabitants
Table 94 Us Market For Immunosuppressants After Blood Stem Cell Transplantation, Through 2007 ($ Millions)
Table 95 Dominant Bone Replacement Procedures, Us, 1995-1999
Table 96 Projected Major Bone Replacement Procedures, Us, Through 2007
Table 97 Us And Workdwide Implant Market Growth, Through 2007 ($ Billions)
Table 98 Us And World Values Of Bone Allograft Market, Through 2007 ($ Millions)
Table 99 Us Sales Of Bone Allografts By Type, Through 2007 ($ Millions)
Table 100 Number Of Heart Valve Transplants And Bypass Operations In The Us, 1995-1999
Table 101 Us And World Heart Valve Transplant Market, Through 2007
Table 102 Projected Number Of Heart Valve Transplants And Bypass Operations In The Us, Through 2007
Table 103 Us Market Of Human Skin-Based Products, Through 2007
Table 104 Skin Grafts In The Us, 1995-1999
Table 105 Estimated Incidence Of Venous Ulcers In The Over 64 Population, Us, Through 2007
Table 106 Estimated Incidence Of Diabetic Foot Ulcers, Us
Table 107 Tendon, Cartilage, And Muscle Grafts, Us, 1995-1999
Table 108 Cosmetic Surgery Trends In The Us, 1997-2001
Table 109 Growth In Us Of Popular Cosmetic Surgeries Making Use Of Donated Human Tissue, 1999-2001
Table 110 Projected Growth In Popular Us Cosmetic Surgery Markets For Skin Products, Through 2007 (Number Of Procedures)
List of Figures
Summary Figure:
Us Organ And Tissue Transplantation Markets, 2002 And 2007 ($ Millions)
Figure 1 Issue Grafting In The Us, 2002 - 2007 (Number Of Procedures)
Figure 2 Us Sales Of Immunosuppressives By Type, 1999-2007 ($ Millions)
Figure 3 The Us Kidney Transplant Market, 2002-2007 ($ Millions)
Figure 4 Us Whole Pancreas Transplantation Market, 2000-2007 ($ Millions)
Figure 5 Liver Transplant Market In The Us, 2000-2007 ($ Millions)
Figure 6 Treatment Costs For Acute Liver Failure: Transplantation And Bioartificial Liver, Us, 2000-2007 ($ Millions)
Figure 7 Us Heart-Lung Transplant Market, 2000-2007 ($ Millions)
Figure 8 Us Lung Transplantation Market, 2000-2007 ($ Millions)
Figure 9 Us Small Bowel Transplantation Market, 2000-2007 ($ Millions)
Figure 10 Corneal Transplants And Market In The Us, 2001-2007 ($ Millions)
Figure 11 Us And Worldwide Implant Market Growth, 2002-2007 ($ Billions)
Figure 12 Us And World Values Of Bone Allograft Market, 2002-2007 ($ Millions)
Figure 13 Us Sales Of Bone Allografts By Type, 2000-2007 ($ Millions)